These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 38627144)
1. Immunogenicity of quadrivalent human papillomavirus vaccine among Alaska Native children aged 9-14 years at 5 years after vaccination. Davis BM; Blake I; Panicker G; Meites E; Thompson G; Geis J; Bruden D; Fischer M; Singleton R; Unger ER; Markowitz LE; Bruce MG Vaccine; 2024 May; 42(14):3277-3281. PubMed ID: 38627144 [TBL] [Abstract][Full Text] [Related]
2. A prospective cohort study of immunogenicity of quadrivalent human papillomavirus vaccination among Alaska Native Children, Alaska, United States. Bruce MG; Meites E; Bulkow L; Panicker G; Hurlburt D; Lecy D; Thompson G; Rudolph K; Unger ER; Hennessy T; Markowitz LE Vaccine; 2020 Sep; 38(42):6585-6591. PubMed ID: 32814639 [TBL] [Abstract][Full Text] [Related]
3. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study. Toh ZQ; Russell FM; Reyburn R; Fong J; Tuivaga E; Ratu T; Nguyen CD; Devi R; Kama M; Matanitobua S; Tabrizi SN; Garland SM; Sinha R; Frazer I; Tikoduadua L; Kado J; Rafai E; Mulholland EK; Licciardi PV Clin Infect Dis; 2017 Apr; 64(7):852-859. PubMed ID: 28034886 [TBL] [Abstract][Full Text] [Related]
4. Antibody persistence after a single dose of quadrivalent HPV vaccine and the effect of a dose of nonavalent vaccine given 3-8 years later - an exploratory study. Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER Hum Vaccin Immunother; 2019; 15(2):503-507. PubMed ID: 30252583 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and persistence of immunity of a quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. MacIntyre CR; Shaw P; Mackie FE; Boros C; Marshall H; Barnes M; Seale H; Kennedy SE; Moa A; Hayen A; Chughtai AA; O'Loughlin EV; Stormon M Vaccine; 2016 Aug; 34(36):4343-50. PubMed ID: 27406936 [TBL] [Abstract][Full Text] [Related]
6. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine. Zhang Z; Zhang J; Xia N; Zhao Q Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820 [TBL] [Abstract][Full Text] [Related]
7. Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort. Murahwa AT; Mudzviti T; Mandishora RSD; Chatindo T; Chanetsa P; Pascoe M; Shamu T; Basera W; Luethy R; Williamson AL Viruses; 2024 Jan; 16(1):. PubMed ID: 38275972 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Sankaranarayanan R; Prabhu PR; Pawlita M; Gheit T; Bhatla N; Muwonge R; Nene BM; Esmy PO; Joshi S; Poli UR; Jivarajani P; Verma Y; Zomawia E; Siddiqi M; Shastri SS; Jayant K; Malvi SG; Lucas E; Michel A; Butt J; Vijayamma JM; Sankaran S; Kannan TP; Varghese R; Divate U; Thomas S; Joshi G; Willhauck-Fleckenstein M; Waterboer T; Müller M; Sehr P; Hingmire S; Kriplani A; Mishra G; Pimple S; Jadhav R; Sauvaget C; Tommasino M; Pillai MR; Lancet Oncol; 2016 Jan; 17(1):67-77. PubMed ID: 26652797 [TBL] [Abstract][Full Text] [Related]
9. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent? Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995 [TBL] [Abstract][Full Text] [Related]
10. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study. Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422 [TBL] [Abstract][Full Text] [Related]
11. Long term follow up of persistence of immunity following quadrivalent Human Papillomavirus (HPV) vaccine in immunocompromised children. MacIntyre CR; Shaw PJ; Mackie FE; Boros C; Marshall H; Seale H; Kennedy SE; Moa A; Chughtai AA; Trent M; O'Loughlin EV; Stormon M Vaccine; 2019 Sep; 37(37):5630-5636. PubMed ID: 31402238 [TBL] [Abstract][Full Text] [Related]
12. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549 [TBL] [Abstract][Full Text] [Related]
13. Sustainability of neutralising antibodies induced by bivalent or quadrivalent HPV vaccines and correlation with efficacy: a combined follow-up analysis of data from two randomised, double-blind, multicentre, phase 3 trials. Mariz FC; Gray P; Bender N; Eriksson T; Kann H; Apter D; Paavonen J; Pajunen E; Prager KM; Sehr P; Surcel HM; Waterboer T; Müller M; Pawlita M; Lehtinen M Lancet Infect Dis; 2021 Oct; 21(10):1458-1468. PubMed ID: 34081923 [TBL] [Abstract][Full Text] [Related]
14. Persistence of Immunity When Using Different Human Papillomavirus Vaccination Schedules and Booster-Dose Effects 5 Years After Primary Vaccination. Lazcano-Ponce E; Torres-Ibarra L; Cruz-Valdez A; Salmerón J; Barrientos-Gutiérrez T; Prado-Galbarro J; Stanley M; Muñoz N; Herrero R; Hernández-Ávila M J Infect Dis; 2019 Jan; 219(1):41-49. PubMed ID: 30085139 [TBL] [Abstract][Full Text] [Related]
15. Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants. Murata S; Shirakawa M; Sugawara Y; Shuto M; Sawata M; Tanaka Y Papillomavirus Res; 2020 Dec; 10():100205. PubMed ID: 32827835 [TBL] [Abstract][Full Text] [Related]
16. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510 [TBL] [Abstract][Full Text] [Related]
17. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine. Gilca V; Sauvageau C; Boulianne N; De Serres G; Crajden M; Ouakki M; Trevisan A; Dionne M Hum Vaccin Immunother; 2015; 11(3):732-8. PubMed ID: 25714044 [TBL] [Abstract][Full Text] [Related]
18. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. Pinto LA; Kemp TJ; Torres BN; Isaacs-Soriano K; Ingles D; Abrahamsen M; Pan Y; Lazcano-Ponce E; Salmeron J; Giuliano AR J Infect Dis; 2016 Oct; 214(8):1276-83. PubMed ID: 27511896 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Hillman RJ; Giuliano AR; Palefsky JM; Goldstone S; Moreira ED; Vardas E; Aranda C; Jessen H; Ferris DG; Coutlee F; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI Clin Vaccine Immunol; 2012 Feb; 19(2):261-7. PubMed ID: 22155768 [TBL] [Abstract][Full Text] [Related]
20. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up. Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]